Treatment of pediatric pulmonary hypertension

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 509-524

  Hawkins, Amy ^a   Tulloh, Robert ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

Congenital heart disease; Pulmonary hypertension; Pulmonary vascular resistance; Pulmonary vasodilators

Indexed keywords

AMBRISENTAN; AMLODIPINE; BERAPROST; BOSENTAN; ESTRADIOL DERIVATIVE; ILOPROST; NIFEDIPINE; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNIPROST; ENDOTHELIN RECEPTOR; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN DERIVATIVE;

APOPTOSIS; BLALOCK HANLON OPERATION; CHILD HEALTH CARE; CLINICAL FEATURE; CLINICAL TRIAL; EXTRACORPOREAL OXYGENATION; HISTOPATHOLOGY; HUMAN; LIVER TOXICITY; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; NITRIC OXIDE THERAPY; OXYGEN THERAPY; PATHOGENESIS; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; SUPPLEMENTATION; SURGICAL TECHNIQUE; ALGORITHM; CHILD; DRUG ANTAGONISM; DRUG POTENTIATION; ECHOCARDIOGRAPHY; PHYSIOLOGY; PRACTICE GUIDELINE; PULMONARY ARTERY;

ALGORITHMS; CHILD; ECHOCARDIOGRAPHY; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROSTAGLANDINS I; PULMONARY ARTERY; RECEPTORS, ENDOTHELIN;

EID: 70149084865     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: None     Document Type: Review

References (167)

1. Andrews R, Tulloh R. Pulmonary hypertension in pediatrics. Curr Opin Ped. 2002;14:603-605.
2. Gibbs J. Recommendations on the management of pulmonary hypertension in clinical practice. Heart. 2001;86(Suppl 1):1-13.
3. Tulloh R. Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatr Respir Rev. 2005;6:174-180.
4. Freed MD. Invasive diagnostic and therapeutic techniques. Part 1: cardiac catheterisation. In Adams FH, Emmanouilides GC, Riemenschneider TA, editors. Heart Disease in Infants, Children and Adolescents. London: Williams and Wilkins; 2000. p. 130-146.
5. Andrews R, Tulloh R. Atrial septal defect with failure to thrive in infancy: hidden pulmonary vascular disease? Pediatr Cardiol. 2002;23:528-530.
6. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):5S-12S.
7. Rabinovich M. Pathobiology of pulmonary hypertension. Annu Rev Pathol. 2007;2:369-399.
8. Rabinovitch M, Keane JF, Norwood WI, Castaneda AR, Reid L. Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation. 1984;69:655-667.
9. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation. 1989;80:1198-1206.
10. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodelling in pulmonary hypertension. Prog Cardiovasc Dis. 20202;45:173-202.
11. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216-223.
12. Widlitz A, Barst R. Pulmonary arterial hypertension in children. Eur Respir J. 2003;21:155-176.
13. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343-349.
14. Rich S. Clinical insights into the pathogenesis of primary pulmonary hypertension. Chest. 1998;114(3 Suppl):237S-241S.
15. National Pulmonary Hypertension Centres of the UK and Ireland. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax. 2008;63:ii1-ii41.
16. Manes A, Campana C. Pulmonary hypertension: classification and diagnostic algorithm. Ital Heart J. 2005;6:834-839.
17. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart. 2006;92:664-670.
18. Atz AM, Adatia I, Lock JE, Wessel DL. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol. 1999;33:813-819.
19. Mikhail G, Gibbs J, Richardson M, Wright G, Khaghani A, Banner N. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J. 1997;18(9):1499-1504.
20. Muthurangu V, Taylor A, Andriantsimiavona R, Hegde S, Miquel ME, Tulloh R. Novel method of quantifying pulmonary vascular resistance by use of simultaneous invasive pressure monitoring and phase-contrast magnetic resonance flow. Circulation. 2004;110(7):826-834.
21. Muthurangu V, Atkinson D, Sermesant M, Miquel ME, Hegde S, Johnson R. Measurement of total pulmonary arterial compliance using invasive pressure monitoring and MR flow quantification during MR-guided cardiac catheterization. Am J Physiol Heart Circ Physiol. 2005;289(3):H1301-H1306.
22. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005;26:858-863.
23. Langleben D, DeMarchie M, Laporta D, Spanier AH, Schlesinger RD, Stewart DJ. Endothelin-1 in acute lung injury and the adult respiratory distress syndrome. Am Rev Respir Dis. 1993;148(6 Pt 1):1646-1650.
24. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002;165(3):398-405.
25. Hervé P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99(3):249-254.
26. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70-75.
27. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest. 2003;111(9):1339-1346.
28. Bando K, Turrentine MW, Sharp TG, Sekine Y, Aufiero TX, Sun K. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J Thorac Cardiovasc Surg. 1996;112(6):1600-1607; discussion 1607-1609.
29. Lindberg L, Olsson AK, Jögi P, Jonmarker C. How common is severe pulmonary hypertension after pediatric cardiac surgery? J Thorac Cardiovasc Surg. 2002;123(6):1155-1163.
30. Ohsumi H, Sakamoto M, Yamazaki T, Okumura F. Effects of fentanyl on carotid sinus baroreflex control of circulation in rabbits. Am J Physiol. 1989;256(3 Pt 2):R625-R631.
31. Adriaenssens T, Delcroix M, Van Deyk K, Budts W. Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome. Eur Heart J. 2006;27(12):1472-1477.
32. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131(6):1917-1928.
33. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25(24):2243-2278.
34. Taylor CJ, Derrick G, McEwan A, Haworth SG, Sury MR. Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. Br J Anaesth. 2007;98(5):657-661.
35. Sandoval J, Aguirre JS, Pulido T, Martinez-Guerra ML, Santos E, Alvarado P. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med. 2001;164(9):1682-1687.
36. Steudel W, Hurford WE, Zapol WM. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology. 1999;91(4):1090-1121.
37. Adatia I, Barrow SE, Stratton PD, Ritter JM, Haworth SG. Effect of intracardiac repair on biosynthesis of thromboxane A2 and prostacyclin in children with a left to right shunt. Br Heart J. 1994;72(5):452-456.
38. Beghetti M, Habre W, Friedli B, Berner M. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J. 1995;73(1):65-68.
39. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damsak K, Straube R. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics. 1998;101(3 Pt 1):325-334.
40. Thébaud B, Arnal JF, Mercier JC, Dinh-Xuan AT. Inhaled and exhaled nitric oxide. Cell Mol Life Sci. 1999;55(8-9):1103-1112.
41. Lowson SM. Alternatives to nitric oxide. Br Med Bull. 2004;70:119-131.
42. Ortitz RM, Cilley RE, Bartlett RH. Extracorporeal membrane oxygenation in pediatric respiratory failure. Pediatr Clin North Am. 1987;34(1):39-46.
43. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. New Eng J Med. 1997;336:597-604.
44. Kinsella JP, Abman SH. Inhaled nitric oxide therapy in children. Paediatr Respir Rev. 2005;6(3):190-198.
45. Abman SH. Neonatal pulmonary hypertension: a physiologic approach to treatment. Pediatr Pulmonol Suppl. 2004;26:127-128.
46. Levin DL, Heymann MA, Kitterman JA, Gregory GA, Phibbs RH, Rudolph AM. Persistent pulmonary hypertension of the newborn infant. J Pediatr. 1976;89(4):626-630.
47. Hermon M, Golej J, Burda G, Marx M, Trittenwein G, Pollak A. Intravenous prostacyclin mitigates inhaled nitric oxide rebound effect: A case control study. Artif Organs. 1999;23(11):975-978.
48. Göthberg S, Edberg KE, Tang SF, Michelsen S, Winberg P, Holmgren D, et al. Residual pulmonary hypertension in children after treatment with inhaled nitric oxide: a follow-up study regarding cardiopulmonary and neurological symptoms. Acta Paediatr. 2000;89(12):1414-1419.
49. Bizzarro M, Gross I. Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease. Cochrane Database Syst Rev. 2009;4:CD005055.
50. Macrae DJ, Field D, Mercier JC, et al. Inhaled nitric oxide therapy in neonates and children: reaching a European consensus. Intensive Care Med. 2004;30(3):372-380.
51. Chou P, Blei ED, Shen-Schwarz S, Gonzalez-Crussi F, Reynolds M. Pulmonary changes following extracorporeal membrane oxygenation: autopsy study of 23 cases. Hum Pathol. 1993;24(4):405-412.
52. Clark RH, Huckaby JL, Kueser TJ, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension: 1 year follow-up. J Perinatol. 2003;23(4):300-303.
53. Fakioglu H, Totapally BR, Torbati D, Raszynski A, Sussmane JB, Wolfsdorf J. Hypoxic respiratory failure in term newborns: clinical indicators for inhaled nitric oxide and extracorporeal membrane oxygenation therapy. J Crit Care. 2005;20(3):288-293.
54. Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in children with severe pulmonary hypertension. Heart. 2007;(6):739-743.
55. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart. 2006;92(5):664-670.
56. Wimmer M, Salzer U, Schlemmer M, Marx M, Proll E. Experience with long-term nifedipine therapy in paediatric cardiological patients. Padiatr Padol. 1990;25(3):181-193.
57. Houde C, Bohn DJ, Freedom RM, Rabinovitch M. Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators. Br Heart J. 1993;70(5):461-468.
58. Mawatari E, Hongo M, Sakai A, et al. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering. Clin Exp Pharmacol Physiol. 2007;34(7):594-600.
59. Adatia I, Perry S, Landzberg M, Moore P, Thompson JE, Wessel DL. Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation. J Am Coll Cardiol. 1995;25(7):1656-1664.
60. Weimann J, Ullrich R, Hromi J, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology. 2000;92(6):1702-1712.
61. Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation. 2003;108(2):239-244.
62. Leibovitch L, Matok I, Paret G. Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension. Drugs. 2007;67(1):57-73.
63. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. 2005;111(24):3274-3280.
64. Rossi R, Nuzzo A, Lattanzi A, Coppi F, Modena MG. Sildenafil improves endothelial function in patients with pulmonary hypertension. Pulm Pharmacol Ther. 2008;21(1):172-177.
65. Diller GP, van Eijl S, Okonko DO, et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation. 2008;117(23):3020-3030.
66. Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag. 2006;2(4):411-422.
67. Spring RM, Ulrich S, Huber LC, et al. Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance. Pulm Pharmacol Ther. 2008;21(3):516-521.
68. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157.
69. Bharani A, Mathew V, Sahu A, et al. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J. 2003;55:55-59.
70. Atz AM, Lefler AK, Fairbrother DL, Uber WE, Bradley SM. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg. 2002;124(3):628-629.
71. Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J. 2002;54(4):404-409.
72. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med. 2005;258(3):199-215.
73. Della Torre F, Della Torre E, Di Berardino F. Sildenafil in pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(1):78-79.
74. Teixeira CE, Priviero FB, Webb RC. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther. 2006;316(2):654-661.
75. Toque HA, Teixeira CE, Priviero FB, Morganti RP, Antunes E, De Nucci G. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol. 2008;154(4):787-796.
76. Lang IM, Bonderman D, Kneussl M, Marx M. Paediatric pulmonary vascular disease. Paediatr Respir Rev. 2004;5(3):238-248.
77. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328(24):1732-1739.
78. Cacoub P, Dorent R, Nataf P, Carayon A. Endothelin-1 in pulmonary hypertension. N Engl J Med. 1993;329(26):1967-1968.
79. Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(4):697-704.
80. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48-54.
81. Giannakoulas G, Dimopoulos K, Gatzoulis MA. Bosentan in mild pulmonary hypertension. Lancet. 2008;372(9651):1730-1731; author reply 1731.
82. Beghetti M, Hoeper MM, Kiely DG, Carlsen J, Schwierin B, Segal ES. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res. 2008;64(2):200-204.
83. Van Loon RLE, Hoendermis ES, Duffels MGJ, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J. 2007;154:776-782.
84. Apostolopoulou SC, Rammos S. Sitaxsentan in pulmonary arterial hypertension. Chest. 2003;123(5):1772; author reply 1772-1773.
85. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest. 2002;121(6):1860-1868.
86. Benza RL, Barst RJ, Galie N, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest. 2008;134(4):775-782.
87. Mehta PK, Simpson L, Lee EK, Lyle TA, McConnell ME, Book WM. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects. Tex Heart Inst J. 2008;35(3):256-261.
88. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010-3019.
89. Tudor A, Muşat A, Bari M, Peţa D, Cochior D. Observations on peripheral microcirculation in young hypertensive patients. Rom J Intern Med. 2005;43(1-2):73-78.
90. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99(9):1197-1208.
91. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99(14):1858-1865.
92. Rosenzweig EB, Widlitz AC, Barst RJ. Pulmonary arterial hypertension in children. Pediatr Pulmonol. 2004;38(1):2-22.
93. Takaoka S, Faul JL, Doyle R. Current therapies for pulmonary arterial hypertension. Semin Cardiothorac Vasc Anesth. 2007;11:137-148.
94. Barst RJ. Diagnosis and treatment of pulmonary artery hypertension. Curr Opin Pediatr. 1996;8(5):512-519.
95. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):56S-61S.
96. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800-804.
97. Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol. 2007;99(5):696-698.
98. Vizza CD, Sciomer S, Morelli S, et al. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart. 2001;86(6):661-665.
99. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(12):2119-2125.
100. Baker SE, Hockman RH. Inhaled iloprost in pulmonary arterial hypertension. Ann Pharmacother. 2005;39(7-8):1265-1274.
101. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322-329.
102. Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Deliv. 2008;21(1):1-12.
103. Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J. 2006;70(2):174-178.
104. Alapati VR, McKenzie C, Blair A, Kenny D, MacDonald A, Shaw AM. Mechanisms of U46619- and 5-HT-induced contraction of bovine pulmonary arteries: role of chloride ions. Br J Pharmacol. 2007;151(8):1224-1234.
105. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol. 2000;522 Pt 2:177-185.
106. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005;25(9):1767-1775.
107. Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 2004;94(3):385-393.
108. Fukumoto Y, Tawara S, Shimokawa H. Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors. Tohoku J Exp Med. 2007;211(4):309-320.
109. Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005;91(3):391-392.
110. Janosi T, Peták F, Fontao F, Morel DR, Beghetti M, Habre W. Differential roles of endothelin-1 ETA and ETB receptors and vasoactive intestinal polypeptide in regulation of the airways and the pulmonary vasculature in isolated rat lung. Exp Physiol. 2008;93(11):1210-1219.
111. Tofovic SP, Zhang X, Zhu H, Jackson EK, Rafikova O, Petrusevska G. 2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. Vascul Pharmacol. 2008;48(4-6):174-183.
112. Gurbanov E, Shiliang X. The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension. Eur J Cardiothorac Surg. 2006;30(3):499-507.
113. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation. 2008;118:1486-1495.
114. Altieri DC. Survivin and apoptosis control. Adv Cancer Res. 2003;88:31-52.
115. Guerard P, Rakotoniaina Z, Goirand F, et al. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotalineinduced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol. 2006;373(6):401-414.
116. Rakotoniaina Z, Guerard P, Lirussi F, Rochette L, Dumas M, Goirand F, Bardou M. Celecoxib but not the combination of celecoxib + atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(3):241-251.
117. McMurtry MS, Bonnet S, Michelakis ED, Bonnet S, Haromy A, Archer SL. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol. 2007;293(4):L933-L940.
118. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99(3):249-254.
119. MacLean MR, Deuchar GA, Hicks MN, et al. Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation. 2004;109(17):2150- 2155.
120. Marcos E, Adnot S, Pham MH, et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med. 2003;168(4):487-493.
121. Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation. 2005;111(21):2812-2819.
122. Kawut SM, Horn EM, Berekashvili KK, Lederer DJ, Widlitz C, Rosenzweig EB. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther. 2006;19(5):370-374.
123. Arima M, Kanoh T, Takagi A, Tanimoto K, Oigawa T, Matsuda S. Clinical features of acute pulmonary thromboembolism in younger patients. Circ J. 2003;67(4):330-333.
124. Castillo L, Beaumier L, Ajami AM, Young VR. Whole body nitric oxide synthesis in healthy men determined from [15N] arginine-to-[15N] citrulline labeling. Proc Natl Acad Sci U S A. 1996;93:11460-11465.
125. McMullan DM, Bekker JM, Parry AJ, et al. Alterations in endogenous nitric oxide production after cardiopulmonary bypass in lambs with normal and increased pulmonary blood flow. Circulation. 2000;102(suppl):III172- III178.
126. Barr FE, Beverley H, VanHook K, et al. Effect of cardiopulmonary bypass on urea cycle intermediates and nitric oxide levels after congenital heart surgery. J Pediatr. 2003;142:26-30.
127. Gorenflo M, Ullmann MV, Eitel K, et al. Plasma L-arginine and metabolites of nitric oxide synthase in patients with left-to-right shunt after intracardiac repair. Chest. 2005;127(4):1184-1189.
128. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol. 2002;29(2):282-287.
129. Hoeper MM. Drug treatment of pulmonary arterial hypertension: current and future agents. Drugs. 2005;65(10):1337-1354.
130. Fasnacht MS, Tolsa JF, Beghetti M; Swiss Society for Pulmonary Arterial Hypertension. The Swiss registry for pulmonary arterial hypertension: the paediatric experience. Swiss Med Wkly. 2007;137(35-36):510-513.
131. Mogollón MV, Lage E, Cabezón S, et al. Combination therapy with sildenafil and bosentan reverts severe pulmonary hypertension and allows heart transplantation: case report. Transplant Proc. 2006;38(8):2522- 2523.
132. Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2006;3:CD004434.
133. Driscoll JA, Chakinala MM. Medical therapy for pulmonary arterial hypertension. Expert Opin Pharmacother. 2008;9(1):65-81.
134. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425-1436.
135. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257-1263.
136. Haraldsson A, Kieler-Jensen N, Ricksten SE. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vasc Anesth. 1996;10(7):864-868.
137. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol. 2008;64(1):43-50.
138. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521-530.
139. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation. 1995;91(7):2028-2035.
140. Rich S, Lam W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension. Am J Cardiol. 1983;51(9):1560-1561.
141. Law MA, Grifka RG, Mullins CE, Nihill MR. Atrial septostomy improves survival in select patients with pulmonary hypertension. Am Heart J. 2007;153(5):779-784.
142. Hausknecht MJ, Sims RE, Nihill MR, Cashion WR. Successful palliation of primary pulmonary hypertension by atrial septostomy. Am J Cardiol. 1990;65(15):1045-1046.
143. Sandoval J, Gaspar J, Pulido T, Bautista E, Martínez-Guerra ML, Zeballos M. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol. 1998;(2):297-304.
144. Cheever KH. An overview of pulmonary arterial hypertension: risks, pathogenesis, clinical manifestations, and management. J Cardiovasc Nurs. 2005;20(2):108-116; quiz 117-118.
145. Huddleston CB, Bloch JB, Sweet SC, de la Morena M, Patterson GA, Mendeloff EN. Lung transplantation in children. Ann Surg. 2002;236(3):270-276.
146. Aurora P, Edwards LB, Christie J, et al. Registry of the International Society for Heart and Lung Transplantation: eleventh official pediatric lung and heart/lung transplantation report - 2008. J Heart Lung Transplant. 2008;27(9):978-983.
147. Haworth SG. Role of the endothelium in pulmonary arterial hypertension. Vascul Pharmacol. 2006;45(5):317-325.
148. Galie' N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet. 2008;371:2093-2100.
149. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30:394-403.
150. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112:485-491.
151. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296-302.
152. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425-434.
153. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-1123.
154. Langleben D, Christman BW, Barst RJ, et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J. 2002;143:E4.
155. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496-1502.
156. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
157. Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension. 1: A randomized, placebo-controlled, doubleblind, crossover study. J Am Coll Cardiol. 2004;43:1149-1153.
158. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353-359.
159. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169(4):441-447.
160. Galie N, Ghofrani HA, Torbicki A, et al. The Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157.
161. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005;171:1292-1297.
162. Singh T, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151:851.e1-851.e5.
163. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47(10):2049-2056.
164. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-1263.
165. Hoeper M, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seifarth HJ, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Resp J. 2006;4:691-694.
166. Hislop A. Developmental biology of the pulmonary circulation. Paediatr Respir Rev. 2005;6(1):35-43.
167. Torres F. Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension. Int J Clin Pract. 2007;61(10):1756-1765.